In an exchange filing, Sun Pharma said it has received approval from the South African Health Products Regulatory Authority (SAHPRA) and plans to launch the product in the country in the coming days.
The generic semaglutide will be available as a pre-filled, multi-dose injectable pen in two strengths—2 mg/1.5 mL and 4 mg/3 mL—allowing for once-weekly dosing.
The drug has been approved for use as an adjunct to diet and exercise in adults with inadequately controlled Type 2 diabetes.
South Africa is the second market after India where Sun Pharma has secured approval for its generic semaglutide.
Aalok Shanghvi, Chief Operating Officer, Sun Pharma, said, “This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals.”
The company noted that South Africa faces a rising burden of Type 2 diabetes, driven by urbanisation and changing lifestyles, making broader access to effective therapies increasingly important.
Shares of Sun Pharma were trading 0.84% higher at ₹1,959 on Wednesday. The stock has gained about 14% so far this year.
Also read: Explained: You can use crypto to trade commodities 24/7
